该公司预计将于2023年在1H公布ADORING1和ADORING2的顶线结果。 参考来源:FDA Approves Dermavant’s Vtama® (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults: first topical novel chemical entity launched for psoriasis in the U.S. in 25 years.新闻发布,Dermavant Sciences;2022...
At day 29, 14 patients (73.7%) had a ≥1-grade improvement in PGA score and six patients (31.6%) had a ≥2-grade improvement; four patients (21.1%) achieved treatment success (PGA 0 or 1 and ≥2-grade improvement). CONCLUSION :Tapinarof cream 1% QD was well tolerated, with ...
1% tapinarof cream was superior to placebo [OR: 8.3 (5.5, 13.0), 8.3 (5.9, 13.0), 7.3 (5.1, 11.0)] and calcipotriol in the treatment of psoriasis at 4, 8, and 12?weeks, and the incidence of adverse events was higher than that with placebo [OR: 3.3 (2.6, 4.3)] and ...
A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitisatopic dermatitisGSK2894512tapinaroftherapeutic aryl hydrocarbon receptor modulating agentBackground:Safe and efficacious topical treatments are needed for atopic dermatitis (AD).Peppers, ...